Abstract:Background & Aims Chronic viral infections present serious public health challenges; however, direct-acting antivirals (DAAs) are now able to cure nearly all patients infected with the hepatitis C virus (HCV), representing the only cure of a human chronic viral infection to date. DAAs provide a valuable opportunity to study immune pathways in the reversal of chronic immune failures in an in vivo human system. Methods To leverage this opportunity, we used plate-based single-cell RNA-seq (scRNA-seq) to deeply profile myeloid cells from liver fine needle aspirates (FNAs) in HCV patients before and after DAA treatment. We comprehensively characterized liver neutrophils, eosinophils, mast cells, conventional dendritic cells (cDCs), plasmacytoid dendritic cells (pDCs), classical monocytes, non-classical monocytes, and macrophages, and defined fine-grained subpopulations of several cell types. Results We discovered cell-type-specific changes post-cure, including an increase in MCM7+STMN1+ proliferating CD1C+ cDCs, which may support restoration from chronic exhaustion. We observed an expected downregulation of interferon stimulated genes (ISGs) post-cure as well as an unexpected inverse relationship between pre-treatment viral load and post-cure ISG expression in each cell type, revealing a link between viral loads and sustained modifications of the host's immune system. We found an upregulation of PD-L1/L2 expression in ISG-high neutrophils and IDO1 expression in eosinophils, pinpointing cell subpopulations crucial for immune regulation. We identified three recurring gene programs shared by multiple cell types, distilling core functions of the myeloid compartment. Conclusion This comprehensive scRNA-seq atlas of human liver myeloid cells in response to a cure of chronic viral infections reveals principles of liver immunity and provides immunotherapeutic insights. Impact and implications Chronic viral liver infections continue to be a major public health problem. Single-cell characterization of liver immune cells in hepatitis C and post-cure provides unique insights into the architecture of liver immunity contributing to the resolution of the first curable chronic viral infection of humans. Multiple layers of innate immune regulation during chronic infections and persistent immune modifications after cure are revealed. Researchers and clinicians may leverage these findings to develop methods to optimize the post-cure environment for HCV and develop novel therapeutic approaches. Clinical trial number NCT02476617.

Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNASeq

Single-cell atlas of the liver myeloid compartment with cure of chronic viral hepatitis

Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis

Single-cell RNA-sequencing of virus-specific cellular immune responses in chronic hepatitis B patients

Efficacy of antiviral therapy and host-virus interactions visualised using serial liver sampling with fine-needle aspirates

Biological basis for functional cure of chronic hepatitis B

Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients

Fine‐Tuning TLR‐7‐Based Therapy for Functional HBV Cure

Imprinted immune abnormalities in liver transplant patients cured of hepatitis C with antiviral drugs

Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity

Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy

A CRISPR-based system to investigate HBV cccDNA biology

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism

Cell-type-specific expression analysis of liver transcriptomics with clinical parameters to decipher the cause of intrahepatic inflammation in chronic hepatitis B

Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production

A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments

Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure

Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B

Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma

The scientific basis of combination therapy for chronic hepatitis B functional cure

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo